Results for tag: "Galectin Inhibitor"

Galectin inhibitors are a class of oncology drugs that target galectin proteins, which are involved in the regulation of cell growth and survival. Galectin inhibitors are used to treat a variety of cancers, including breast, lung, and colorectal cancer. They work by blocking the activity of galectin proteins, which can help to reduce tumor growth and spread. Galectin inhibitors are also being studied for their potential to treat other diseases, such as autoimmune disorders and inflammatory diseases. The galectin inhibitor market is growing rapidly, driven by the increasing prevalence of cancer and the need for more effective treatments. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some companies in the galectin inhibitor market include Merck, Pfizer, Novartis, and AstraZeneca. Show Less Read more